[Laxigal effectiveness in constipation of various etiology]

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Constipation is a common gastrointestinal disorder affecting a significant portion of the population.
• Irritable Bowel Syndrome (IBS), inert colon, and dolichocolon are conditions often associated with chronic constipation.
• Stimulant laxatives are frequently used for managing constipation, but their long-term efficacy and safety profiles require ongoing evaluation.

Purpose of the Study:

• To evaluate the efficacy and safety of laxigal (sodium picosulfate) in patients suffering from constipation associated with IBS, inert colon, and dolichocolon.
• To determine optimal dosing and potential for dose reduction with prolonged use of laxigal.
• To assess the impact of laxigal on bowel function and potential adverse effects.

Main Methods:

• A study involving 66 patients aged 38-73 years with diagnosed IBS, inert colon, or dolichocolon.
• Administration of laxigal (sodium picosulfate) at a dosage of 10-24 droplets before bedtime.
• Assessment of treatment outcomes based on patient-reported effects (good, satisfactory) and monitoring for adverse events.

Main Results:

• Laxigal demonstrated a good effect in 64% (42 patients) and a satisfactory effect in 36% (24 patients).
• Higher efficacy was observed in patients with IBS and dolichocolon compared to those with inert colon.
• Long-term therapy (3+ weeks) allowed for a 30-50% dose reduction without compromising effectiveness.
• No significant adverse effects such as diarrhea, abdominal pain, electrolyte imbalance, or hepatorenal dysfunction were reported.

Conclusions:

• Laxigal (sodium picosulfate) is an effective treatment for constipation in patients with IBS, inert colon, and dolichocolon.
• The medication is well-tolerated, with a favorable safety profile and no significant adverse effects.
• Dose reduction is feasible with extended use, indicating sustained efficacy and potential for long-term management of constipation.